ArticleBMC bioinformatics2017
Integration of RNA-Seq data with heterogeneous microarray data for breast cancer profiling.
Article in BMC bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Unveiling immune-related gene signatures in triple negative breast cancer through integrated transcriptomic analysis.BioMedicine · 2026Article
- A supervised Bayesian method for time (re)annotation of transcriptomics data.NAR genomics and bioinformatics · 2025Article
- Network-Based Integrative Analysis to Identify Key Genes and Corresponding Reporter Biomolecules for Triple-Negative Breast Cancer.Cancer medicine · 2025Article
- Generation of synthetic whole-slide image tiles of tumours from RNA-sequencing data via cascaded diffusion models.Nature biomedical engineering · 2025Article
- A state-of-the-art review of diffusion model applications for microscopic image and micro-alike image analysis.Frontiers in medicine · 2025Review
- EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology.NPJ breast cancer · 2024Article
- Harmonizing heterogeneous transcriptomics datasets for machine learning-based analysis to identify spaceflown murine liver-specific changes.NPJ microgravity · 2024Article
- A Role of Multi-Omics Technologies in Sheep and Goat Meats: Progress and Way Ahead.Foods (Basel, Switzerland) · 2023Review
- Enhancing the prediction of IDC breast cancer staging from gene expression profiles using hybrid feature selection methods and deep learning architecture.Medical & biological engineering & computing · 2023Article
- Multi-Omics Approaches to Improve Meat Quality and Taste Characteristics.Food science of animal resources · 2023Review
- Cross-Platform Transcriptomic Data Integration, Profiling, and Mining inMicrobiology spectrum · 2023Article
- Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma.Cancer medicine · 2023Article
- DEG (differentially expressed gene) or not DEG that is the question: Should we compare between datasets or not?Journal of molecular and cellular cardiology plus · 2023Article
- Machine-Learning-Based Late Fusion on Multi-Omics and Multi-Scale Data for Non-Small-Cell Lung Cancer Diagnosis.Journal of personalized medicine · 2022Article
- Expression pattern of non-coding RNAs in non-functioning pituitary adenoma.Frontiers in oncology · 2022Article
- Non-small-cell lung cancer classification via RNA-Seq and histology imaging probability fusion.BMC bioinformatics · 2021Article
- Integration of transcriptomic data identifies key hallmark genes in hypertrophic cardiomyopathy.BMC cardiovascular disorders · 2021Article
- Identifying Conserved GenericJournal of fungi (Basel, Switzerland) · 2021Article
- Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.Clinical pharmacology and therapeutics · 2021Review
- Processing and Analysis of RNA-seq Data from Public Resources.Methods in molecular biology (Clifton, N.J.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNowadays, many public repositories containing large microarray gene expression datasets are available. However, the problem lies in the fact that microarray technology are less powerful and accurate than more recent Next Generation Sequencing technologies, such as RNA-Seq. In any case, information from microarrays is truthful and robust, thus it can be exploited through the integration of microarray data with RNA-Seq data. Additionally, information extraction and acquisition of large number of samples in RNA-Seq still entails very high costs in terms of time and computational resources.This paper proposes a new model to find the gene signature of breast cancer cell lines through the integration of heterogeneous data from different breast cancer datasets, obtained from microarray and RNA-Seq technologies. Consequently, data integration is expected to provide a more robust statistical significance to the results obtained. Finally, a classification method is proposed in order to test the robustness of the Differentially Expressed Genes when unseen data is presented for diagnosis.
resultsThe proposed data integration allows analyzing gene expression samples coming from different technologies. The most significant genes of the whole integrated data were obtained through the intersection of the three gene sets, corresponding to the identified expressed genes within the microarray data itself, within the RNA-Seq data itself, and within the integrated data from both technologies. This intersection reveals 98 possible technology-independent biomarkers. Two different heterogeneous datasets were distinguished for the classification tasks: a training dataset for gene expression identification and classifier validation, and a test dataset with unseen data for testing the classifier. Both of them achieved great classification accuracies, therefore confirming the validity of the obtained set of genes as possible biomarkers for breast cancer. Through a feature selection process, a final small subset made up by six genes was considered for breast cancer diagnosis.
conclusionsThis work proposes a novel data integration stage in the traditional gene expression analysis pipeline through the combination of heterogeneous data from microarrays and RNA-Seq technologies. Available samples have been successfully classified using a subset of six genes obtained by a feature selection method. Consequently, a new classification and diagnosis tool was built and its performance was validated using previously unseen samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.